Nxera Pharma Co., Ltd.

OTCPK:SOLT.F Stock Report

Market Cap: US$657.2m

Nxera Pharma Valuation

Is SOLT.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOLT.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOLT.F ($8.05) is trading below our estimate of fair value ($20.45)

Significantly Below Fair Value: SOLT.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOLT.F?

Key metric: As SOLT.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SOLT.F. This is calculated by dividing SOLT.F's market cap by their current revenue.
What is SOLT.F's PS Ratio?
PS Ratio3.5x
SalesJP¥29.28b
Market CapJP¥101.77b

Price to Sales Ratio vs Peers

How does SOLT.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SOLT.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average20.5x
EYPT EyePoint Pharmaceuticals
13.7x44.8%US$627.9m
PCRX Pacira BioSciences
1.2x0.6%US$810.3m
LQDA Liquidia
57.7x59.6%US$901.4m
ELTP Elite Pharmaceuticals
9.3xn/aUS$658.9m
SOLT.F Nxera Pharma
3.5x9.3%US$101.8b

Price-To-Sales vs Peers: SOLT.F is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (20.5x).

Price to Sales Ratio vs Industry

How does SOLT.F's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
BHC Bausch Health Companies
0.3x1.5%US$2.93b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
SOLT.F 3.5xIndustry Avg. 2.8xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SOLT.F is expensive based on its Price-To-Sales Ratio (3.5x) compared to the US Pharmaceuticals industry average (2.6x).

Price to Sales Ratio vs Fair Ratio

What is SOLT.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOLT.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SOLT.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOLT.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$13.30
0%
33.3%US$25.19US$8.40n/a10
Nov ’25US$7.25
US$13.53
+86.7%
32.8%US$25.50US$8.50n/a10
Oct ’25US$9.02
US$14.56
+61.4%
30.7%US$27.17US$10.45n/a10
Sep ’25US$9.45
US$14.64
+55.0%
31.6%US$26.91US$10.35n/a9
Aug ’25US$10.15
US$13.59
+33.9%
31.6%US$24.97US$9.60n/a9
Jul ’25n/a
US$13.46
0%
31.8%US$24.86US$9.56n/a9
Jun ’25US$8.87
US$13.46
+51.7%
31.8%US$24.86US$9.56n/a9
May ’25US$9.30
US$13.83
+48.7%
32.5%US$25.69US$9.88n/a9
Apr ’25US$10.80
US$13.95
+29.2%
34.2%US$25.75US$9.91n/a8
Mar ’25US$9.90
US$14.02
+41.6%
33.4%US$25.88US$9.95n/a8
Feb ’25US$9.82
US$14.64
+49.0%
32.2%US$26.34US$10.40n/a8
Jan ’25US$10.00
US$15.75
+57.5%
35.0%US$29.49US$10.81n/a8
Dec ’24US$9.95
US$15.36
+54.4%
37.3%US$28.51US$10.45n/a7
Nov ’24US$9.25
US$15.24
+64.8%
34.2%US$28.07US$10.36US$7.258
Oct ’24US$10.20
US$15.94
+56.3%
35.1%US$28.67US$10.58US$9.027
Sep ’24US$11.18
US$15.94
+42.6%
35.1%US$28.67US$10.58US$9.457
Aug ’24US$13.23
US$17.77
+34.3%
35.7%US$29.77US$10.99US$10.157
Jul ’24US$10.50
US$18.45
+75.7%
47.1%US$31.25US$7.64n/a7
Jun ’24US$22.40
US$24.90
+11.2%
24.3%US$32.01US$12.80US$8.877
May ’24US$19.78
US$24.05
+21.6%
26.8%US$31.43US$13.47US$9.307
Apr ’24US$16.95
US$23.31
+37.5%
28.8%US$30.92US$13.25US$10.806
Mar ’24US$15.90
US$23.00
+44.6%
28.0%US$30.82US$13.21US$9.906
Feb ’24n/a
US$22.41
0%
28.1%US$30.20US$12.94US$9.826
Jan ’24n/a
US$22.41
0%
28.1%US$30.20US$12.94US$10.006
Dec ’23n/a
US$22.41
0%
28.1%US$30.20US$12.94US$9.956
Nov ’23n/a
US$19.35
0%
34.7%US$28.03US$12.01US$9.256

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

4.7%

1Y

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

1.3%

1Y

15.1%